Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology

With Avastin as its bright star, the therapeutic field of anti-angiogenic and vascular targeting drugs in oncology is becoming re-energized. While fragmentation of the oncology market is set to occur as treatment becomes based on tumor growth drivers rather than primary tumor site, the use of targeted therapies, such as anti-angiogenesis, will occur in combination with traditional cytotoxic chemotherapy agents.

Scope of this report

In-depth competitive landscape assessment of the anti-angiogenesis market in oncology

Thorough review of utilized targets in anti-angiogenic and vascular target drug development

Thorough review of approved drugs

Progress analysis of five major cancer indications, including players, drugs, clinical progress and pitfalls

Research and analysis highlights

Companies with the ten highest numbers of clinical trials make up more than 40% of all research and development done in anti-angiogenesis and vascular targeting in onoclogy, but they just constitute 10% of the competitors in the field.

More than 100 anti-angiogenic drugs have been described with one or more targets. These 75 drug targets are a mixture of weaker and stronger targets in angiogenesis.

The prostate cancer market is reaching maturity, and major players’ sales have been eroded by the launch of various LHRH agonist depot formulations, BioSeeker identifies that angiogenesis inhibitors will be the most promising for future treatment of prostate cancer.

Key reasons to read this report

Understand the clinical and strategic challenges to the commercialization of anti-angiogenic and vascular targeting drugs

Assess opportunities and risks for the continued development of anti-angiogenic and vascular targeting agents in five major cancer indications.

Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development

Some of the almost 100 drugs included in this analysis

2-methoxyestradiol, AMG-706, ATN-161, AZD-2171, bevacizumab, combretastatin A-4 prodrug, enzastaurin hydrochloride, everolimus, neovastat, PTK/ZK, sorafenib tosylate, squalamine, thalidomide, vitaxin, XL-999, ZD-6474, volociximab etc.

Some of the more than 100 companies included in this analysis

Adherex, Aeterna Zentaris, Amgen, AstraZeneca, Bayer, Celgene, Chugai, Eli Lilly, EntreMed, Eisai, Exelixis, Genaera, Genentech, Hoffmann-La Roche, Merck KGaA, Novartis, OXiGENE, PDL BioPharma, PharmaMar, Wilex etc.

October 2006 Pages 125
Table of Contents
Price: $2,999.00 / GBP1,499.50